寡转移性激素敏感性前列腺癌立体定向体部放疗后全身治疗升级
这项回顾性、观察性、多机构研究纳入119例≤5个转移灶的寡转移性激素敏感性前列腺癌患者,评估立体定向体部放疗(SBRT)后的肿瘤学结局,中位全身治疗升级无生存期(STE-FS)为33.4个月(95%CI 26.6–40.1),局部控制率95%,≥3级毒性仅1例。
要点
- 中位随访34个月,中位STE-FS为33.4个月(95%CI 26.6–40.1),中位OS未达到,PFS为22.7个月(95%CI 18.6–32.3)。
- SBRT后PSA稳定或下降者87例(73.1%),局部控制率95%,远处转移44例(37%),生化复发21例(17.7%),前列腺复发2例(1.7%)。
- 多因素分析显示SBRT后生化反应是STE-FS的独立预后因素,≥3级毒性1例。
核心结论
- 对于寡转移性激素敏感性前列腺癌患者,SBRT具有优异的局部控制和耐受性,是延迟全身治疗升级及其副作用的有吸引力的方法。
- 作者指出,精准选择适合SBRT的患者需要更多数据和更长随访及更大样本量,有待正在进行的随机试验结果。
研究设计与样本
- 回顾性、观察性、多机构研究,纳入119例≤5个转移灶的寡转移性激素敏感性前列腺癌患者,均接受SBRT。
- 主要终点为SBRT后全身治疗升级无生存期(STE-FS),同时报告局部、远处、前列腺及孤立生化复发、无进展生存期(PFS)和总生存期(OS),并分析STE-FS预后因素及毒性。
主要发现
- 中位STE-FS为33.4个月(95%CI 26.6–40.1),中位OS未达到,PFS为22.7个月(95%CI 18.6–32.3)。
- SBRT后PSA稳定或下降者87例(73.1%),进展事件(局部、转移、前列腺、孤立生化复发)72例(60.5%),其中照射区域内复发6例(局部控制率95%)。
- 远处转移44例(37%),生化复发21例(17.7%),前列腺复发2例(1.7%)。
- 多因素分析显示SBRT后生化反应是STE-FS的独立预后因素,≥3级毒性发生1例。
关键数值与推荐
- 寡转移性激素敏感性前列腺癌患者接受SBRT,转移灶数目≤5个。
- 主要终点STE-FS的中位值为33.4个月(95%CI 26.6–40.1),中位PFS为22.7个月(95%CI 18.6–32.3),中位OS未达到。
- 局部控制率为95%,≥3级毒性1例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出,精准选择适合SBRT的患者需要更多数据和更长随访及更大样本量,有待正在进行的随机试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the oncological outcome after stereotactic body radiation therapy (SBRT) for oligometastatic hormone-sensitive prostate cancer (omHSPC) patients. MATERIALS-METHODS: In this retrospective, observational, multi-institutional study, omHSPC patients (≤5 metastases) underwent SBRT. Primary endpoint was systemic therapy escalation-free survival (STE-FS) after SBRT. Local (LR), distant (DR), prostatic (PR) and isolated biochemical (iBR) relapses were reported with progression-free survival (PFS) and overall survival (OS). Prognostic factors for STE-FS were investigated. Toxicity was reported. RESULTS: From 01/07 to 09/19, 119 pts with omHSPC underwent SBRT. With a MFU of 34 months [12-97], median STE-FS was 33.4 months (95%CI 26.6---40.1). Median OS was not reached and PFS was 22.7 months (CI95% 18.6---32.3). Post-SBRT-PSA remained stable or decreased in 87 pts (73.1%). Progression events (LR, MR, PR, iBR) were observed in 72 pts (60.5%), among whom 6 relapsed in the irradiated area (local control rate: 95%). DR, BR, PR were observed in 44 pts (37%), 21pts (17.7%) and 2 pts (1.7%) respectively. In multivariate analysis, post-SBRT biochemical response was an independent prognostic factor for STE-FS. Grade ≥ 3 toxicity occurred in 1pt. CONCLUSION: With excellent local control and tolerance, SBRT for omHSPC patients represents an attractive approach to defer systemic therapeutic escalation and prevent its side effects. Accurate patient selection for SBRT requires more data with longer follow-up and higher numbers of patients pending the results of upcoming randomized trials.
引用
- Baron D, Pasquier D, Pace-Loscos T, et al. Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer. Clin Transl Radiat Oncol. 2023. PMID: 37701481. doi:10.1016/j.ctro.2023.100673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。